Phase 1 Study of Treatment for Advanced HER2-Positive Cancers Gets Underway

Phase 1 Study of Treatment for Advanced HER2-Positive Cancers Gets Underway
A Phase 1 clinical trial assessing the safety and efficacy of the anti-HER2 antibody ZW25 in advanced or metastatic HER2-positive cancers has just dosed its first patient, according to a recent announcement by Zymeworks, the therapy’s manufacturer. “We are excited to have begun enrollment in this initial study of ZW25,” Diana Hausman, Zymeworks’ chief medical officer, said in

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *